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Walker (1-3) has shown that congenital osteopetrosis in microphthalmic (mi) ~ mice is 
associated with a defect in bone resorption which can be reversed by injecting cells from 
the bone marrow or spleen of normal animals into irradiated mutants (2). Conversely, 
osteopetrosis  could  be  produced  by  injecting  spleen  cells  from  mutants  into  normal 
recipients  (3). Abnormalities  of osteoclast morphology and  histochemistry have been 
reported in this mutant and in incisor absent (ia) rats with congenital osteopetrosis (4-6). 
While Walker's studies and earlier work on amphibia by Fischman and Hay (7) suggest 
that circulating mononuclear cells  may be  the  precursors for osteoclasts,  neither  the 
specific cell types which reverse the defect in osteopetrosis nor the mechanism by which 
they act have been identified. By analogy with some immune responses it is possible that 
the formation of the osteoclasts requires cooperation among several cell types including 
both effector cells and helper cells which might secrete humoral mediators. The osteo- 
clast-activating factor (OAF), which is produced by phytohemagglutinin (PHA)-activated 
human  mononuclear  cells  (8-10),  is  a  potent  stimulus  for  osetoclast-mediated  bone 
resorption in vitro. The cell source for this factor is not certain, but available data suggest 
that it is derived from activated lymphocytes, but that these require  macrophages as 
helper cells (11). The role of OAF in physiologic skeletal "development  is unknown. It has 
been suggested that OAF might be involved in marrow development and that a defect in 
production  or  response  to  this  mediator  might  be  important  in  the  pathogenesis  of 
osteopetrosis. 
The  present  studies  were  undertaken  to  develop  an  in  vitro  model  which 
would enable us to analyze more completely the defects responsible for osteope- 
trosis in animal models. The mi mouse was selected for initial studies because of 
ease of identification of the different genotypes. 
Tissue cultures of long bones and calvaria from mi mice were compared with 
bones from homozygous normal animals and heterozygous carriers. Bones from 
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mi  mice showed a  generalized  defect  in bone resorption with marked  impair- 
ment of the resorptive response to both human and mouse OAF as well as other 
known  stimulators  of osteoclastic  bone resorption  including parathyroid  hor- 
mone  (PTH)  (12),  prostaglandin  E2  (PGE2)  (13),  1,25  dihydroxy  vitamin  D3 
[1,25(OH)2D3]  (14), and vitamin A  (12). Bone formation was not impaired in mi 
mice and could be inhibited by PTH and OAF. OAF production did not appear to 
be impaired since supernatant fluid of PHA-activated spleen cells from mi mice 
contained as much bone resorbing activity as supernates from normal animals. 
Methods 
Mice, heterozygous for the mi recessive gene, were obtained from Dr. D. W. Walker, The Johns 
Hopkins University School of Medicine, Baltimore, Md., and from The Jackson Laboratory, Bar 
Harbor,  Maine.  Separation of the various genotypes was possible in fetal as well as newborn 
animals because mi mutants have no eye pigment while heterozygotes have a  small amount and 
homozygous normals have a fully pigmented eye. Except for one experiment in which fetal age was 
estimated from bone size and development, the studies were carried out after a  single overnight 
mating to permit precise dating of pregnancy. 
Long Bone Cultures.  The technique was similar to that used for measuring resorption in fetal 
rat long bones (12,  15). The pregnant mice were injected with 4~Ca on the day before sacrifice. On 
the 16th to 19th day the fetuses were removed, the shafts of the radius and ulna dissected free of 
soft tissue and cartilage, and precultured for 18-24 h in a chemically defined medium, BGJ, at 37°C 
in an atmosphere of 5% CO2 in air. Subsequently the bones were transferred to the same medium 
supplemented with 4 mg/ml bovine serum albumin, to which various stimulators of bone resorp- 
tion were  added,  and cultured  for 3  days.  45Ca in the  medium  and bone were  measured  and 
resorption estimated from the percent of 45Ca released. Bones killed by three cycles of freezing and 
thawing were used to correct for any differences in the exchange of 45Ca by bones from the different 
genotypes. 
Experiments Combining Bones from Different Genotypes.  In some experiments, 45Ca release 
from  long bones  of mi  normal  or  heterozygous  mice  were  compared  when  cultured  alone  or 
together with long bones from unlabeled animals. Labeled bones were co-cultured with unlabeled 
bones from the same or different genotype. The labeled and unlabeled bones were placed together 
on a  2 mm square Millipore filter and the cultures were maintained for 6 days with a  change of 
medium at 3 days. 
Calvarial Cultures.  Newborn mice were used (21 days post-mating). The bones were labeled 
with 4aCa by injection of the mother 3 days before birth. The flat, central portions of the frontal and 
parietal bones were dissected,  care being taken to preserve the periosteum.  Half calvaria were 
incubated in BGJ supplemented with 5% heat-inactivated human serum in a  manner similar to 
the long bone cultures.  The bones were  cultured for one or two 3-day periods.  In some of the 
experiments the bones were transferred to Ehrlenmeyer flasks at the end of the resorption culture 
period for studies of bone collagen synthesis. 
Bone Collagen  Synthesis.  After 3-6 days culture, bones were transferred to 25 ml Ehrlenmeyer 
flasks with 2 ml of growth medium containing i mM proline and no serum, gassed with 5% CO2 and 
air,  stoppered,  and incubated for 3  h.  Labeled proline  (2,3-~H-proline; 5t~Ci/ml; New  England 
Nuclear, Boston, Mass.) was added for the last 2 h. At the end of incubation the bones were washed 
with 5% TCA,  acetone, and ether; weighed; and homogenized. 3H-proline in collagen was deter- 
mined  by  digestion  with  repurified  bacterial  collagenase  by  the  method  of Peterkofsky  and 
Diegelmann  (17).  Labeled collagenase-digestible protein  (CDP) and noncollagen protein  (NCP) 
were determined and the percent collagen synthesis calculated using a factor of 5.4 to correct for 
the relative abundance of proline in collagen and noncollagen protein. 
Lysosomal Enzyme  Measurements.  To  measure  lysosomal  enzyme  activity,  calvaria  were 
homogenized in 0.1% Triton in water and aliquots of bone homogenate or medium were incubated 
with appropriate  buffers and substrates using standard  methods  (18).  For measurement of fl- 
glucuronidase (fl-G1) the substrate was phenolphthalein-fl-glucosiduronate, for n-fi-acetylglucosa- 
minidase  (AG) the substrate was the nitrophenylglycoside and for cathepsin D  (Cath D),  3H- 
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TABLE  I 
Effect of  Parathyroid Hormone (N-PTH, 100 ng/ml) and Human OAF (1/20 Dilution) on 
Release  of 45Ca from Cultured Long Bone Shafts of Microphthalmic (mi/mi), 
Heterozygous  (mi/ +) , and Normal (+/+) 16-19-Day Fetal Mice 
Treatment 
mi/mi  mi/+  +/+ 
% Total 45Ca  Treated/  % Total 45Ca  Treated/  % Total 45Ca  Treated/ 
released  control  released  control  released  control 
Control  10.2 _+ 0.6  -  11.7 ±  0.7  11.1 ±  2.0 
Killed  10.1  ±  0.3  0.99  9.8  ±  0.3*  0.84  9.2  ±  0.5*  0.83 
PTH  12.1 ± 0.3*  1.19  20.2 ± 0.8*  1.73  22.9 ±  1.3"  2.07 
OAF  11.3 ±  0.3*  1.13  15.7 ± 0.7*  1.35  19.9 ± 2.3*  1.79 
Values are means ± standard error for 6-10 bones cultured for 3 days. 
* Significantly different from control, P  < 0.05. 
enzyme present in bone and medium that was released into the medium during a 3 day culture 
period. The recovery of enzyme from bone homogenate appeared to be complete, since the initial 
values for enzyme in homogenates of the calvaria and in the medium plus bone of calvaria killed 
by repeated freezing and thawing and then incubated for several days were similar. Moreover, no 
additional enzyme activity could be obtained by centrifugation and re-extraction of the homoge- 
nate. 
Cultures of Mouse Spleen for OAF.  Homozygous normal and mi newborn mice spleens were 
used. The remaining heterozygous animals were returned to the mother and ultimately added to 
the breeding colony. The spleens were minced and the cells dispersed by repeated pipetting, the 
cell suspension pelleted by brief centrifugation and resuspended in BGJ medium at 10  e mononu- 
clear cells/ml. 10 ml of cell suspension was incubated in a 150 mm Petri dish with 1% PHA (PHA- 
M; Grand Island Biological Corp., Grand Island, N. Y.). After 24 h the supernate was removed, 
centrifuged, and the clear supernate frozen. This crude supernate which contained bone-resorbing 
activity is referred to as mouse OAF. In addition, a human OAF preparation partially purified by 
Sephadex G100 chromatography, as previously described (9), was used in some cultures. 
Materials.  In addition to the OAF preparations, bovine parathyroid hormone 1-84 (N-PTH; 
kindly provided by the National Institutes of Health, Bethesda, Md.), synthetic bovine PTH 1-34 
(B-PTH, Beckman Instruments, Inc., Fullerton, Calif.), PGE2 (kindly provided by the Upjohn Co., 
Kalamazoo, Mich.), 1,25(OH)2D3 (kindly provided by Hoffman-La Roche, Inc., Nutley, N. J.), and 
vitamin A (retinol; Eastman Organic Chemicals Div., Eastman Kodak Co., Rochester, N. Y.) were 
used. 
Results 
Long Bone  Cultures.  The  radius  and  ulna  from  16-  to  19-day  fetal  mice 
provided satisfactory material  for measurement  of bone resorptive response to 
stimulators.  Bones from  homozygous normal  or heterozygous  animals  showed 
up  to  twofold  increase  in  45Ca  release  in  response  to  PTH  and  a  significant 
response  to partially  purified human  OAF  (Table  I).  Control  resorption  rates 
were  low,  but the difference from killed bones was significant for homozygous 
normals  and  for  heterozygotes.  In  contrast,  bones  from  mi/mi  mice  showed 
minimal  response  to  PTH  or OAF  and  no  control  resorption.  The  response  to 
bones from heterozygotes appeared  less than  that for homozygous norma]s, and 
in another  experiment  (Table II) the response to a  submaximal  dose of PTH was 
significantly less  in  bones  from  heterozygous  animals  (P  <  0.05).  Histologic 
studies  showed  that  both  heterozygous  and  normal  bone  treated  with  PTH 
contained numerous  osteoclasts on the bone surface, with loss of matrix.  Stable 
calcium content of the bone was reduced by treatment  with PTH by a percentage 860  OSTEOPETROTIC  BONE  IN  ORGAN  CULTURE 
TABLE II 
Effect of Parathyroid Hormone (N-PTH) on Release of 45Ca from Cultured Long Bone 
Shafts of Microphthalmic (mi/mi) , Heterozygous (rail+), and Normal (+/+) 17-Day 
Fetal Mice 
mi/mi  mi/+  +/+ 
Treat-  % Total 
ment  Treated/  % Total  45Ca Treated/  % Total  ~sCa Treated/  4~Ca re- 
control  released  control  released  control  leased 
Control  14.2 -+ 0.7  -  16.0 +- 0.5  -  16.9 +- 0.3  - 
Killed  13.5 +- 1.0  0.95  14.4 -+ 0.4  0.90  14.7 _+ 0.4*  0.87 
PTH  (10  13.8 -+ 1.9  0.97  17.8 +_ 1.0  1.11  25.7 +_ 2.4*  1.52 
ng/ml) 
PTH  (100  16.5 -+ 2.3  1.16  35.5 -+ 3.7*  2.21  47.4 +- 7.5*  2.80 
ng/ml) 
Values  are  means -+ standard  error  for  9-17  bones  cultured  for  3  days. 
*  Significantly  different  from  control,  P < 0.05. 
TABLE IXI 
Effect of Combined Culture with Unlabeled Bones and Treatment with 
Parathyroid Hormone (N-PTH, 40 ng/ml) on Release of 4~Ca from Cultured 
Long Bone Shafts of Microphthalmic (mi/mi) vs. Heterozygous (mi/ +  ) or 
Normal (+ / +) 17-Day Fetal Mice 
% Total  ~sCa  released 
Treatment  Labeled mi/mi  Labeled rni/ + 
bone  or + / + bone 
PTH alone  31.5 _+ 1.7  65.8 +- 11.3 
PTH plus unlabeled mi/+ or +/+ bone  32.9 -+ 1.7  68.6 -+ 6.9 
PTH plus unlabeled mi/rni bone  31.2 _+ 0.1  61.6 -  1.8 
Values  are  means +_ standard  error  for  three  to  seven  bones  cultured  for  6 days. 
similar  to  the amount of  45Ca  lost.  In  contrast, mi/mi  bones showed no identifia- 
ble osteoclasts on bone surfaces and did not lose stable calcium with PTH. 
To test  the possibilities  that normal bone cells  were producing a humoral 
factor essential for osteoclast activation or that osteopetrotic bones contain an 
inhibitor of  osteoclasts,  paired cultures of  mutant and normal or heterozygous 
bones were maintained in culture with the addition of PTH.  There was no 
difference in 45Ca release when  mi/mi  bones were cultured  alone,  with paired 
bones  from  normal  or  heterozygous  animals  or  with  paired  bones  from  mi 
animals  (Table III).  Similarly,  the data  for bones from normals  and  heterozy- 
gotes, which are pooled, showed no difference in response whether  cultured with 
unlabeled bones from the same genotypes or from mi animals. Since these small 
bones (less than  1 mg wet weight) were cultured in 0.5 ml of medium,  the data 
do not rule out the existence of a humoral  factor which was ineffective because of 
dilution. 
Culvaria  Cultures.  Further  studies were carried out on half calvaria from 
mi/mi,  heterozygous,  and normal  animals,  because  (a) they had  been used in 
previous  studies  of  osteopetrosis,  (b)  they  show  relatively  greater  rates  of 
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TABLE  IV 
Effects of Parathyroid Hormone (~-PTH, 400 ng/ml), PGE2 (10 4  M) 
1,25(OH)2D3 (10 -8 M) Vitamin A  (Vit A, 10 -5 M), and OAF from Normal or 
Mutant Mice (OAF mi/mi and OAF +/+, 1/8 Dilution) on Release of 45Ca 
from Cultured Calvaria of Microphthalmic (mi/mi), Heterozygous (mi/ +), 
and Normal (+/+) Newborn Mice 
861 
% Total  4sCa  released 
mi/mi  mi/+  +/+ 
Control  13.2  _  0.9  23.1  -+  1.0 
Killed  11.3 _+ 0.8  9.8 -+ 0.3* 
PTH  13.9 -- 1.9  32.1 -- 4.6* 
PGE2  13.4 -+ 0.4  38.4 -+ 1.9" 
1,25(OH)2D3  11.6 -- 0.2  36.4 -+ 2.3* 
Vit A  12.1 ___ 1.2  30.1 +- 1.1" 
OAF mi/mi 1/8  14.8 _+ 1.1  36.2 _+. 4.4* 
OAF +/+ 1/8  12.2 -+ 3.0  37.8 -+ 1.6" 
23.3 +- 2.0 
11.3 -+ 0.7* 
39.2 -+ 2.8* 
38.2 -+ 5.7* 
36.7 -+ 5.9* 
Values are means _+ standard error for 5-26 bones cultured for 3 days. 
* Significantly  different from control, P  < 0.05. 
lysosomal enzyme release and collagen synthesis. Both heterozygotes and homo- 
zygous normals showed substantial  control resorption  and responded to PTH, 
PGE2, and 1,25(OH)2D3 (Table IV). PTH at supramaximal initial concentration 
had a greater effect on normal bone than on bone from heterozygotes. However, 
the response to PGE2 and 1,25(OH)2D3 at supramaximal concentrations was not 
different  for  bones  from  normals  or  heterozygotes.  Bones  from  mi/mi  mice 
showed no significant control resorption and no response to any of the stimula- 
tors. 
Because the number of  bones was limited,  only mi/rni  and heterozygote bone 
was  used  to  test  the 45Ca  response to  vitamin A and  mouse OAF. Vitamin A was 
found to stimulate resorption  of  bone from heterozygotes but not from mi/mi 
animals. When tested  on bones from heterozygotes,  the bone-resorbing activity 
in supernates  of PHA-stimulated spleen cell cultures from mi/mi  mice was as 
great as for spleen cells from homozygous normals.  However, mouse OAF did 
not stimulate resorption of mi/mi bone. In other studies (data not shown) mouse 
OAF from normal and mutant animals was assayed at several dilutions and no 
difference in potency or dose-response curve was observed. 
An increase in the lysosomal enzyme release into the medium was associated 
with stimulation of resorption by PTH or vitamin A  in cultures of normal bone 
and was similar for all three enzymes tested  (Table V). In contrast,  bone from 
mi/mi animals showed no increase in enzyme release with stimulation.  Control 
release of enzymes was similar for mutant and normal bone, and there was no 
difference in total enzyme content of normal and mutant bone. In other experi- 
ments (data not shown) the medium content of fl-G1 was increased with stimula- 
tion of bone resorption by PGE2 in normal but not in mutant bones. 
PTH  and  human  OAF  are  inhibitors  of bone collagen synthesis  in  vitro at 
high concentrations  (10).  Mouse calvaria were cultured for 3-6 days and trans- 
ferred to a  growth medium to measure proline incorporation into CDP  (Table 
VI). Bones from mi/mi mutants and normal or heterozygous mice incorporated 862  OSTEOPETROTIC  BONE  IN  ORGAN  CULTURE 
TABLE  V 
Effects of  Parathyroid Hormone (fl-PTH 400 ng/ml) and Vitamin A  (10-5 M) on Release 
of fl-Gl, n-[3-Acetyl  Glucosaminidase  (AG) and Cath D from Cultured Newborn Mouse 
Calvaria 
mi/mi 
% release 
fl-G1  AG  Cath D 
Control  11.2 +- 1.2  11.2 _+  1.1  8.8 -+ 0.9 
PTH  9.9 ± 0.6  9.3 -+ 1.2  9.2 ±  1.1 
VitA  14.0±0.9  12.2  ± 2.1  12.2  ±2.0 
+/+ 
% release 
B-G1  AG  Cath D 
11.3 ±  1.8  10.4  ± 0.9  9.4 ±  1.0 
28.3 ± 2.0*  25.1 _  1.3"  23.8  ±  1.1" 
21.6 ±  1.9"  19.9  -+ 1.7"  19.8  ±  1.4" 
Values are means _+ standard error for six bones cultured for percent of total enzyme released 
into medium in 48 h. 
* Significantly  greater than control, P  < 0.01. 
TABLE  VI 
Effect of Parathyroid Hormone (fl-PTH, 400 ng/ml) and OAF from Normal Mice on 
Incorporation of Labeled Proline into CDP and NCP of Cultured Calvaria from 
Microphthalmic (mi/mi) and Heterozygous or Normal (mi/ + or +/+) Mice 
mi/mi 
dpm/t~g dry wt 
CDP  NCP 
% Collagen 
synthesized 
Control  25 -+ 6  36 ± 5  10.5 -+ 1.0 
PTH  12 -  1"  27 ± 3  6.1 _+ 0.6* 
Mouse OAF  11 ±  1"  29 _+ 6  7.0 ±  1.0" 
mi/+ or +/+ 
dpm/tLg dry wt 
CDP  NCP 
% Collagen 
synthesized 
17 ±  1  31-+ 1  8.9 ±0.7 
9 ± 2*  29 = 5  5.4 ± 0.7* 
8 ± 1"  29 ± 2  5.0 ± 0.3* 
Values are means ± standard error of 3 to 12 bone cultures treated for 3-6 days and pulsed with 
3H-proline for the last 2 h of culture. 
* Significantly less than control, P  < 0.05. 
substantial amounts of proline into CDP,  and the value was somewhat higher 
for the mutants. Both PTH and OAF caused similar inhibition of the incorpora- 
tion of labeled proline into collagen in mi/mi and normal or heterozygous mouse 
calvaria. NCP synthesis was not affected. 
Discussion 
The present studies have used techniques for the study of the pathogenesis of 
osteopetrosis  in  vitro  which  should  make  it  possible  to  identify the  specific 
defects in the various animal models of this disorder. The mi  mouse was used 
initially because the defect is severe and it is easy to identify the genotypes in 
fetal  and  newborn animals.  Cultured long bones and calvaria from  mi  mice 
showed decreased spontaneous or control resorption and failed to respond to a 
number of potent stimulators of resorption including PTH, PGE~, 1,25 (OH)2D3, 
vitamin A, and OAF from both human  peripheral leukocyte and mouse spleen 
cultures.  These  results  indicate  that  there  is  a  generalized  bone  resorption 
defect in mi mice which is responsible for the development of osteopetrosis. The 
most  likely explanation for this is an abnormality in osteoclast formation or 
function. We have looked for a  local humoral factor which might be deficient in 
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of mutant and normal  bones provided no evidence for such a  humoral  factor, 
however, dilution or inactivation could have been responsible for the negative 
results. The failure to respond to widely differing stimulators of bone resorption 
makes it extremely unlikely that there was any defect in receptor sites on the 
osteoclasts or their precursors. 
Spleen cells from mi mice produced as much bone-resorbing activity in PHA- 
stimulated  cultures  as  did  spleen  cells  from  normal  animals.  These  results 
suggest that defective OAF production is not important  in the pathogenesis of 
osteopetrosis in this animal  model.  The physiologic role of OAF is not known 
and it is possible that  its spontaneous release may be important  in initiating 
endosteal  bone  resorption.  Failure  of such  release  could  be  responsible  for 
osteopetrosis in other mutants. 
Our results differ from those reported by Marks, who found that 4~Ca loss was 
increased in cultured bones from ia rats, despite evidence that inhibition of bone 
resportion  was  present  in  vivo  (19).  This  discrepancy  could  be  due  to  the 
difference in species, particularly  since the abnormality in resorption is tran- 
sient in the ia rat. Reynolds and his associates found that control resorption was 
impaired in cultures of calvaria from mice with the gray-lethal mutation which 
produces severe osteopetrosis (20).  Reynolds et al.  (20) also demonstrated that 
administration  of a  potent  inhibitor  of bone  resorption,  dichloro-methylene 
diphosphonate,  to newborn normal mice could mimic the osteopetrotic lesion of 
the gray-lethal mutants. 
The studies with calvaria confirmed and extended the results with long bones, 
and provided a model in which biochemical studies were more easily carried out. 
Measurements of several lysosomal enzymes showed that the increased enzyme 
release occurred from normal bones when resorption was stimulated but did not 
occur in mutant bone. Failure of enzyme release has been suggested on the basis 
of morphologic observations of acid phosphatase accumulation in osteoclasts in 
other animal  models of osteopetrosis (4-6).  We found no difference in enzyme 
release  between normal  and  mutant  bone  in  the  absence  of stimulators,  al- 
though  4~Ca release  was different.  Many of the  cells in  the  calvaria  are  not 
resorbing cells.  These may release substantial  amounts of lysosomal enzymes 
due to cell damage or normal  turnover and lead to high  control values which 
could obscure differences in the behavior of bone-resorbing cells. 
Measurements of bone collagen synthesis in this study have indicated that mi 
mutant bone shows inhibition of labeled proline incorporation into collagenase 
digestible protein in response to both PTH and OAF. This is considered to be due 
to inhibition of collagen synthesis rather than changes in amino acid transport 
or precursor pool size because an excess of cold proline was added to the culture 
medium. The results indicate that the bone-forming cells in mutant animals do 
have receptors for PTH and OAF and do not appear to have any functional defect 
in  collagen synthesis or its regulation.  The rate  of proline  incorporation  was 
actually somewhat increased in mutant bone cultures.  Walker has shown that 
proline incorporation is higher in gray-lethal mice in vivo, and that this incorpo- 
ration is inhibited by injections of parathyroid extract, although to a less extent 
than  in  controls  (21).  A  marked  increase  in  bone  formation  has  not  been 
observed  in  most  congenital  osteopetrotic  models,  however,  and  changes  in 864  OSTEOPETROTIC  BONE  IN ORGAN  CULTURE 
osteoblastic activity do  not appear to  be  sufficient to  produce the  defects in 
remodeling and  growth observed.  The fact that osteoblastic activity was  in- 
hibited by PTH and OAF in mi mice while osteoclastic activity was not stimu- 
lated is consistent with the hypothesis that these cells are derived from different 
precursors, and that the defect is in the osteoclast or its progenitor cell. 
Summary 
The mechanism of congenital osteopetrosis in microphthalmic (mi) mice has 
been examined in bone organ cultures. Resorption was measured by the release 
of previously incorporated 4~Ca in fetal long bones and newborn calvaria from mi 
mice and heterozygous or homozygous normal litter mates. Bones from mi mice 
showed a  generalized resorption defect with decreased spontaneous or control 
resorption and failure to respond to parathyroid hormone (PTH), prostaglandin 
E2, 1,25 dihydroxy vitamin Da, vitamin A, or osteoclast activating factor (OAF) 
from human peripheral leukocytes or mouse spleen cells. Bones from heterozy- 
gotes showed a smaller response to PTH than bones from homozygous normals. 
Mutant bones failed to show  an increase in lysosomal enzyme release in re- 
sponse  to  PTH or vitamin A,  agents  which  increased release from bones  of 
homozygous normals. Proline incorporation into collagenase-digestible protein 
was similar in cultures of normal and mutant bone and was inhibited by PTH 
and OAF. These results indicate that congenital osteopetrosis in mi mice is due 
to a generalized defect in the function and hormonal response of osteoclasts and 
suggests that this cell line is separate from the osteoblast cell line which shows 
no impairment of hormonal response. 
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